Duligotuzumab - Genentech

Drug Profile

Duligotuzumab - Genentech

Alternative Names: Anti-HER3/EGFR DAF; MEHD-7945A; RG 7597; RO-5541078

Latest Information Update: 14 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genentech; Roche
  • Developer Genentech
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB-3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Solid tumours
  • Discontinued Colorectal cancer; Head and neck cancer

Most Recent Events

  • 04 Jun 2018 Genentech terminates a phase I trial for Solid tumours (Combination therapy, Late stage disease, Metastatic disease) in USA and Spain (NCT01986166)
  • 23 Apr 2018 Genentech completes a phase I trial for Solid tumours in USA and Spain (NCT01207323)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease) in Spain (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top